Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT00401128
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.

Key Dates

Start date
May 31, 2004
Status verified
Apr 2017
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007

Study Design

Enrollment
9 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Overall response

Locations (1)

FacilityCityStateZIPSite coordinators
Case Comprehensive Cancer CenterClevelandOhio44106-5065-

Find similar trials in Cleveland, OH

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Case Comprehensive Cancer Center· Cleveland, OH

Related Studies